Dabur India Limited (DABUR.BO)
| Previous Close | 600.85 |
| Open | 600.05 |
| Bid | 609.05 x 0 |
| Ask | 609.30 x 0 |
| Day's Range | 600.05 - 612.25 |
| 52 Week Range | 489.00 - 634.00 |
| Volume | |
| Avg. Volume | 143,809 |
| Market Cap | 1.08T |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | 58.64 |
| EPS (TTM) | 10.39 |
| Earnings Date | Aug 01, 2024 |
| Forward Dividend & Yield | 5.50 (0.92%) |
| Ex-Dividend Date | Nov 10, 2023 |
| 1y Target Est | N/A |
- Reuters
UPDATE 1-Dabur India's two units dismissed as defendants in hair relaxer lawsuit in US
Dabur India said on Wednesday a U.S. court had dismissed two of its three subsidiaries as defendants in a lawsuit tying the use of hair relaxer products to ovarian and uterine cancers as well as other health issues. as defendants "for lack of personal jurisdiction" as neither was involved in manufacturing, marketing, distributing or selling hair relaxer products in the United States, the company said in a late filing on Wednesday. However, Dabur's unit Namaste Laboratories continues to be a defendant along with many other industry players such as L'Oreal, Revlon, Luster Products and Avion Industries among others, it added.
- Reuters
Dabur India's units face lawsuits in US, Canada alleging products caused cancer
The consumer goods firm said about 5,400 cases against several companies including its subsidiaries, Namaste Laboratories, Dermoviva Skin Essentials and Dabur International, have been consolidated as a multi-district litigation before a U.S. District Court in Illinois. The units have denied liability and have retained counsel to defend them, the company said.
